Pharmaceutical Product Development, LLC Sustainability Profile
Pharmaceutical Product Development, LLC (commonly known as PPD) is a leading global contract research organisation headquartered in the United States. Founded in 1985, PPD has established itself as a key player in the pharmaceutical and biotechnology industries, providing comprehensive drug development and lifecycle management services. With a strong presence in North America, Europe, and Asia, the company supports clients through innovative solutions tailored to their specific needs. PPD's core offerings include clinical development, laboratory services, and consulting, all designed to accelerate the delivery of new therapies to market. Renowned for its commitment to quality and efficiency, PPD has achieved significant milestones, including numerous successful product launches and partnerships with major pharmaceutical companies. As a trusted partner in the drug development process, PPD continues to enhance its market position through a focus on scientific excellence and operational agility.
DitchCarbon Score
How does Pharmaceutical Product Development, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmaceutical Product Development, LLC's score of 94 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pharmaceutical Product Development, LLC, headquartered in the US, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Thermo Fisher Scientific Inc., and any climate commitments or emissions data would be cascaded from this parent organisation. As part of its corporate family, Pharmaceutical Product Development, LLC aligns with the sustainability initiatives and targets set by Thermo Fisher Scientific Inc. This includes participation in various climate-related initiatives, although specific reduction targets or achievements for Pharmaceutical Product Development, LLC itself have not been disclosed. The absence of direct emissions data highlights the importance of understanding the broader context of climate commitments within the pharmaceutical industry. Companies like Thermo Fisher Scientific Inc. often set ambitious targets to reduce their carbon footprint, which may indirectly influence their subsidiaries. In summary, while specific emissions data for Pharmaceutical Product Development, LLC is not available, the company is part of a larger corporate structure that is committed to sustainability and climate action through its parent organisation, Thermo Fisher Scientific Inc.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 321,190,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 486,151,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Pharmaceutical Product Development, LLC's Industry?
How Carbon Intensive is Pharmaceutical Product Development, LLC's Location?
Pharmaceutical Product Development, LLC's Scope 3 Categories Breakdown
Pharmaceutical Product Development, LLC's Scope 3 emissions, which decreased by 26% last year and decreased by approximately 37% since 2021, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 58% of Scope 3 emissions.
Top Scope 3 Categories
Pharmaceutical Product Development, LLC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pharmaceutical Product Development, LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
